Hepatocellular carcinoma and non-alcoholic fatty liver disease
This article reviews the most updated information about NAFLD-related HCC and provides some insight into strategies that must be considered to reduce its potential disease burden.
Conditions: Apnea, Obstructive Sleep; Obesity Intervention: Device: Bioelectrical Impedance Analysis (BIA) Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital Recruiting
Condition: Gestational Diabetes Interventions: Other: Meal A; Other: Meal B Sponsor: Massachusetts General Hospital Not yet recruiting
Conditions: Melanoma; Non-small Cell Lung Carcinoma (NSCLC); Renal Cell Carcinoma (RCC); Brain Metastases Intervention: Combination Product: LITT + Pembrolizumab Sponsors: University of Florida; Monteris Medical Corporation Not yet recruiting
Ali Mahzari1, Songpei Li1, Xiu Zhou1,2, Dongli Li2, Sherouk Fouda1, Majid Alhomrani1, Wala Alzahrani1, Stephen R. Robinson1 and Ji-Ming Ye1,2* 1Lipid Biology and Metabolic Disease Laboratory, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China The present study investigated the effects of matrine on non-alcoholic steatohepatitis (NASH) in mice induced by a methionine choline-deficient (MCD) diet and the mechanism involved. The study was performed in C57B/6J mice fed a MCD diet for 6 weeks to induce NAS...
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterized as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death; it is associated with extrahepatic manifestations such as chronic kidney disease cardiovascular disease and sleep apnea.
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea.
Abstract Hepatocellular carcinoma is the third most frequent cause of cancer death worldwide, particularly in Asia and Africa. Most cases complicate an underlying liver cirrhosis due to hepatitis B or C chronic virus infection or alcoholic abuse. But, following the current epidemics of obesity and type 2 diabetes, it appears that these diseases, associated in metabolic syndrome, are responsible for non alcoholic fatty liver disease at risk of HCC frequently before the stage of cirrhosis. Recent hypotheses consider that in the near future, cancer deaths due to HCC will overpass in USA those due to breast or colorec...
Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing both in Europe and USA becoming one of the most frequent causes of chronic liver disease and predictably, one of the leading causes of liver transplantation (LT) both for end-stage liver disease and hepatocellular carcinoma. For most transplant teams around the world this will raise many challenges in terms on pre- and post-transplant management. Here we review the multifaceted impact of NAFLD on liver transplantation and will discuss: (1) NAFLD as frequent cause of cryptogenic cirrhosis, en...
Abstract Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and its prevalence is increasing in relation to the epidemics of obesity and type 2 diabetes mellitus, via non-alcoholic fatty liver disease (NAFLD). Unhealthy lifestyles associated with metabolic disorders are per se risk conditions for NAFLD progression, and specific gene polymorphisms may also favor oncogenesis, particularly in the presence of advanced fibrosis or cryptogenic cirrhosis. However, NAFLD-associated HCC may also develop in non-cirrhotic NAFLD and is frequently diagnosed at a more advanced tumor stage, compared with...
Conclusions: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous. (Hepatology 2015)
More News: Alcoholism | Cancer & Oncology | Carcinoma | Cirrhosis | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Fatty Liver Disease (FLD) | Hepatocellular Carcinoma | Infectious Diseases | Liver | Liver Cancer | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology